摘要
肝癌是我国发病率和死亡率均较高的恶性肿瘤之一,其术后转移和复发率高,已成为影响患者预后的重要因素。目前临床上迫切需要能有效准确预测肝癌病情和实时监测疗效及预防转移的技术手段。液体活检具有无创性,敏感性,动态性等特点,近年来在肿瘤早期诊断,个体化用药指导和疗效监控等方面的应用而备受关注。本文将从液体活检的主要研究内容、检测技术以及其在肝癌临床应用中的进展、面临的挑战和展望等方面进行综合述评,希望能为肝癌患者获得更好的临床诊疗提供指导,同时也有力助推肝癌精准医疗的发展。
Hepatocellular carcinoma (HCC) is one of the highest incidence of malignant tumors in our country with the high recurrence rate and high mortality. So how to improve the early diagnosis of HCC is particularly important to improve the early treatment. Liquid biopsy technique with noninvasive, sensitivity, dynamic characteristics has become a liver cancer screening, early targeted medication guide and recurrence monitoring of hot spots. In recent years as the liquid biopsy enrich the research content and the capture and the development of detecting technology, the lung, colorectal, breast and prostate cancer has been recognized by the preliminary clinical application. According to a new study in patients with liver disease status and blood circulating tumor cells (circulating tumor cell, CTC), circulating tumor DNA (circulating tumor DNA, ctDNA) and outside the body (exsome) secretion quantity has the strong correlation. This paper will focus on a comprehensive review from the heterogeneity of cancer of the liver, the challenge of liquid biopsy of liver cancer, liver cancer diagnostic markers and the research progress of liquid biopsy of liver cancer,providing clinical guidance for HCC early diagnosis and treatment.
作者
李宗芳
田红卫
LI Zongfang;TIAN Hongwei(The Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710004,China)
出处
《西部医学》
2019年第7期985-989,993,共6页
Medical Journal of West China
基金
国家自然科学基金(81802456)
陕西省重点研发计划项目(2017ZDCXL-SF-02-05)
关键词
肝细胞癌
液体活检
循环肿瘤细胞
精准医疗
免疫治疗
Hepatocellular carcinoma
Liquid biopsy
Circulafing tumor cell
Precision medicine
Immunotherapy
